retatrutide clinical CutKilo | Phase III retatrutide study demonstrates

However, these effects are usually mild and tend to improve over time

Factors such as previous eye problems, cardiovascular disease, and use of other medications known to increase NAION risk (like PDE5 inhibitors) should be carefully evaluated before starting GLP-1 therapy

Pazarci, P

107 Further, serious risks associated with Tanzeum use include pancreatitis, acute kidney injury, renal impairment, and pneumonia, further limiting its use in specific conditions or susceptible patients

In the CONQUER Trial published in 2011, researchers examined how effective Qsymia was at treating obesity

Medications that activate the GLP-1 receptor can help reduce blood sugar levels and promote weight loss by increasing insulin secretion and decreasing appetite